Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEXLOSNeuro: Dexmedetomidine in Congenital Cardiac Surgery
NCT05369949Phase 4Not yet recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
01
Overview
Phase 4, randomised trial of dexmedetomidine in congenital heart defect (CHD) (2 arms). Primary endpoint: Serum Neurofilament Light Concentration. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
congenital heart defect (CHD)
Beyond the preview
Go deeper on NCT05369949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05369949.